In recent news, the National Institute for Health and Care Excellence (NICE) has been making headlines due to its involvement in the approval and recommendation of various medical treatments and interventions. One notable event is the approval of Rimegepant as a treatment for acute migraines. This decision by NICE allows approximately 145,000 people in England to be eligible for this medication, providing them with a potential solution for managing their migraines.
Another significant development involving NICE is the recommendation of an 'artificial pancreas' device for managing type 1 diabetes. This device aims to improve the management of the condition by automatically monitoring blood glucose levels and delivering insulin as needed. This recommendation highlights NICE's role in evaluating and endorsing innovative technologies that can enhance the quality of life for individuals with chronic conditions.
The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body of the Department of Health in England. It is responsible for providing evidence-based guidance and recommendations on various aspects of healthcare, including the use of health technologies within the National Health Service (NHS). NICE publishes guidelines that cover a wide range of topics, such as the effectiveness and cost-effectiveness of treatments, interventions, and healthcare practices.
NICE plays a crucial role in ensuring that healthcare decisions are based on the best available evidence and are in line with the principles of equity and efficiency. Its recommendations are widely respected and used by healthcare professionals, policymakers, and organizations within the NHS. By evaluating the effectiveness, safety, and cost-effectiveness of interventions, NICE helps to inform healthcare decisions and improve patient outcomes across England.
-
The Chartered Institute of Personnel and Development (CIPD) report highlights the negative experiences women face at work due to menstrual symptoms.
-
Research suggests that replacing potatoes and bread with carrots and spinach can help middle-aged people control their weight.
-
The National Institute for Health and Care Excellence (Nice) has approved Rimegepant as a treatment for acute migraines.
-
The weight-loss drug Wegovy is being made available in the UK, but concerns have been raised about its allocation and limited supplies.
-
Donanemab, a drug that removes a protein called amyloid from the brains of Alzheimer's patients, has been shown to slow clinical decline by up to 35% in a recent trial.
-
Scientists at Cambridge University have found that algae could provide an effective solution to vitamin B12 deficiency in vegans.
-
Pharmaceutical companies are developing new obesity treatments that show promising results.
-
The UK government has launched a £40m pilot scheme to increase access to weight loss drugs and cut NHS waiting lists.
-
Rimegepant was approved for use on Wednesday by the drugs watchdog, the National Institute for Health and Care Excellence (Nice), which said that 145,000 people will be eligible in England.
-
A study of medicines commonly prescribed on the NHS including amitriptyline, duloxetine, fluoxetine (Prozac), citalopram, paroxetine (Seroxat) and sertraline concluded that only duloxetine had reliable evidence for pain relief.
-
Wegovy has been approved for prescription on the NHS in England for weight loss.
-
A genetic test has been recommended for NHS use to identify newborns at risk of hearing loss after taking a specific antibiotic.
-
The NHS has approved eptinezumab, a drug taken as an intravenous infusion, for preventing migraines in adults who have not responded to previous treatments.
-
The National Institute for Health and Care Excellence (Nice) has recommended the use of an 'artificial pancreas' device to help manage type 1 diabetes.
-
NHS approves faecal microbiota transplants (FMT) for patients with recurrent C.diff infections